文献速递血栓与止血

N8-GP(聚乙二醇化重组人凝血因子VIII)在既往未治疗儿童A型血友病患者中的安全性和有效性

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.
PubMed 文献 · Blood Adv · 2023-01-01

pathfinder6是一项正在进行的开放标签3期试验,纳入年龄<6岁的重型A型血友病既往未治疗患者,评估N8-GP的免疫原性、安全性和有效性。80例患者接受至少1剂N8-GP,抑制物发生率为29.9%(高滴度14.9%);65例接受预防治疗平均2.17年,中位年化出血率为1.42,止血成功率为90.5%。

要点

  • N8-GP在既往未治疗儿童重型A型血友病患者中抑制物发生率为29.9%,高滴度抑制物为14.9%。
  • 65例接受N8-GP预防治疗平均2.17年,中位年化出血率1.42,止血成功率90.5%。
  • 17例出现暂时性增量回收率降低,与抗聚乙二醇IgG抗体滴度强时间相关,继续给药后恢复。

核心结论

  • N8-GP预防治疗对重型A型血友病既往未治疗患者的出血发作预防和治疗有效。
  • 抑制物发生率为29.9%。
  • 所有暂时性增量回收率降低并继续N8-GP给药的患者均恢复至预期范围,且无明显疗效缺乏。

研究设计与样本

  • pathfinder6是一项正在进行的开放标签3期试验,纳入年龄<6岁的重型A型血友病既往未治疗患者。
  • 80例患者接受至少1剂N8-GP并纳入分析,其中至少50例患者有至少50个暴露日。
  • 主要终点为凝血因子VIII抑制物(≥0.6 Bethesda单位[BU])的发生率。
  • 该试验在www.clinicaltrials.gov注册,注册号为#NCT02137850。

主要发现

  • 抑制物发生率为29.9%,其中高滴度(>5 BU)抑制物发生率为14.9%。
  • 65例患者接受N8-GP预防治疗平均2.17年,中位年化出血率(四分位距)为1.42(0.76;3.13),止血成功率为90.5%。
  • 17例患者在N8-GP暴露5日内出现暂时性增量回收率降低(定义为连续≥2次增量回收率<0.6 (IU/dL)/(IU/kg)但无抑制物),与抗聚乙二醇免疫球蛋白G抗体滴度有强时间相关性。
  • 增量回收率降低期间,止血反应与总体试验人群相似,未报告与N8-GP相关的超敏反应或非预期新发不良事件。
  • 继续N8-GP给药后增量回收率恢复至预期范围。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

N8-GP (turoctocog alfa pegol) is a recombinant, glycoPEGylated, extended half-life, factor VIII replacement product. Here, we examined the immunogenicity, safety, and efficacy of N8-GP in previously untreated patients (PUPs). pathfinder6 is an ongoing, open-label, phase 3 trial that enrolled PUPs with severe hemophilia A and were aged <6 years. The primary end point was the incidence of factor VIII inhibitors (≥0.6 Bethesda units [BU]). Eighty patients received ≥1 N8-GP dose and were included in this analysis; ≥50 patients had ≥50 exposure days to N8-GP. The inhibitor incidence was 29.9% (14.9% high-titer [>5 BU]). Sixty-five patients received N8-GP prophylaxis for an average of 2.17 years with a median annualized bleeding rate (interquartile range) of 1.42 (0.76; 3.13) and a 90.5% hemostatic success rate. Temporarily decreased incremental recovery (IR), defined as ≥2 consecutive measurements of IR <0.6 (IU/dL)/(IU/kg) but no inhibitors, was observed in 17 patients within 5 exposure days to N8-GP and had a strong temporal correlation with anti-polyethylene glycol immunoglobulin G antibody titers. IR returned within the expected range with continued N8-GP dosing. During the period of decreased IR, hemostatic response was similar to that of the overall trial population, and no hypersensitivity related to N8-GP or unexpected new adverse events were reported. N8-GP prophylaxis was efficacious for the prevention and treatment of bleeding episodes in PUPs with severe hemophilia A. The inhibitor incidence was 29.9%. All patients with temporarily decreased IR continuing on N8-GP dosing returned within the expected range and had no evident lack of efficacy. This trial was registered at www.clinicaltrials.gov as #NCT02137850.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Male C, Königs C, Dey S, et al. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A. Blood Adv. 2023. PMID: 35858373. doi:10.1182/bloodadvances.2022007529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。